These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38687588)

  • 21. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
    Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
    Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.
    Tomita U; Ishimoto Y; Ri M; Kawase Y; Hizukuri Y; Maru C; Nanai K; Nakamura R; Nakayama M; Oguchi-Oshima K; Sumi H; Ohtsuka T; Iida S; Agatsuma T
    Sci Rep; 2024 Mar; 14(1):5135. PubMed ID: 38429446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current use of bispecific antibodies to treat multiple myeloma.
    Lee H; Neri P; Bahlis NJ
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):332-339. PubMed ID: 38066842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
    Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
    Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell exhaustion in multiple myeloma.
    Żyłka K; Kubicki T; Gil L; Dytfeld D
    Expert Rev Hematol; 2024 Jul; 17(7):295-312. PubMed ID: 38919090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
    Pillarisetti K; Edavettal S; Mendonça M; Li Y; Tornetta M; Babich A; Majewski N; Husovsky M; Reeves D; Walsh E; Chin D; Luistro L; Joseph J; Chu G; Packman K; Shetty S; Elsayed Y; Attar R; Gaudet F
    Blood; 2020 Apr; 135(15):1232-1243. PubMed ID: 32040549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
    Holstein SA; Grant SJ; Wildes TM
    J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
    Firestone RS; Socci ND; Shekarkhand T; Zhu M; Qin WG; Hultcrantz M; Mailankody S; Tan CR; Korde N; Lesokhin AM; Hassoun H; Shah U; Maclachlan KH; Rajeeve S; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt S; Murata K; Usmani SZ; Chung DJ
    Blood; 2024 Jul; 144(4):402-407. PubMed ID: 38728378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Talquetamab in multiple myeloma.
    Liu L; Krishnan A
    Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
    Hammons L; Szabo A; Janardan A; Bhatlapenumarthi V; Annyapu E; Dhakal B; Al Hadidi S; Radhakrishnan SV; Narra R; Bhutani D; Thanendrarajan S; Janz S; Zangari M; Lentzsch S; Van Rhee F; Crescencio JCR; D'Souza A; Chakraborty R; Mohan M; Schinke C
    Haematologica; 2024 Mar; 109(3):906-914. PubMed ID: 37646658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
    Laheij AMGA; van de Donk NWCJ
    Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
    Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
    Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
    Frerichs KA; Verkleij CPM; Mateos MV; Martin TG; Rodriguez C; Nooka A; Banerjee A; Chastain K; Perales-Puchalt A; Stephenson T; Uhlar C; Kobos R; van der Holt B; Kruyswijk S; Kuipers MT; Groen K; Vishwamitra D; Skerget S; Cortes-Selva D; Doyle M; Zaaijer HL; Zweegman S; Verona RI; van de Donk NWCJ
    Blood Adv; 2024 Jan; 8(1):194-206. PubMed ID: 38052042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma.
    Kodama T; Kochi Y; Nakai W; Mizuno H; Baba T; Habu K; Sawada N; Tsunoda H; Shima T; Miyawaki K; Kikushige Y; Mori Y; Miyamoto T; Maeda T; Akashi K
    Mol Cancer Ther; 2019 Sep; 18(9):1555-1564. PubMed ID: 31270154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.
    Del Giudice ML; Galimberti S; Buda G
    Cancer Immunol Immunother; 2023 Dec; 72(12):3931-3937. PubMed ID: 37924369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA.
    Casey M; Tu C; Harrison SJ; Nakamura K
    Blood Adv; 2022 Sep; 6(17):5165-5170. PubMed ID: 35830292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.